Pharvaris PHVS
NASDAQ PHVS
$35.25 -0.41 (-1.15%)
As of: Sep 4, 2026 · 3:59 PM EDT

Pharvaris (PHVS) Depreciation & Amortization (CF) (2020 - 2026)

Pharvaris' (PHVS) quarterly Depreciation & Amortization (CF) came in at $122607.5 in Q1 2026, up 10.69% YoY from $110764.5 in Q1 2025, and little changed on a QoQ basis from $122070.9 in Q4 2025.

Analysis

Pharvaris (PHVS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

Pharvaris (PHVS) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $122607.5 in Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 10.69% year-over-year to $122607.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $484235.0 (up 46.84% YoY) and the FY2025 annual result came in at $472659.9, up 62.0% from the prior year.
  • Depreciation & Amortization (CF) steadied at $122607.5 in Q1 2026, from $122070.9 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $122928.5 in Q3 2025 to a low of -$134.5 billion in Q3 2023.
  • A 5-year average of -$7.9 billion and a median of $71038.9 in 2023 frame the typical range for Depreciation & Amortization (CF).
  • Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 898.53% — and 2023, when it plunged 345944944.87%.
  • Tracing PHVS's Depreciation & Amortization (CF) over 5 years: stood at $47108.9 in 2022, then surged by 50.8% to $71038.9 in 2023, then jumped by 36.82% to $97197.3 in 2024, then grew by 25.59% to $122070.9 in 2025, then climbed by 0.44% to $122607.5 in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $122607.5 (Q1 2026), $122070.9 (Q4 2025), and $122928.5 (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 56.50 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 123.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 40.52 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Pharvaris 2.10 Bn 1.73 Bn 85,072.10 208,410.32
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 208,410.32
Mar 31, 2026 122,607.51
Dec 31, 2025 122,070.92
Sep 30, 2025 122,928.48
Jun 30, 2025 116,628.07
Mar 31, 2025 110,764.48
Dec 31, 2024 97,197.30
Sep 30, 2024 -148.29 Bn
Jun 30, 2024 145.41 Bn
Mar 31, 2024 72,085.54
Dec 31, 2023 71,038.93
Sep 30, 2023 -134.54 Bn
Jun 30, 2023 67,212.77
Mar 31, 2023 66,406.59
Dec 31, 2022 47,108.90
Sep 30, 2022 -68.76 Bn
Jun 30, 2022 37,715.12
Mar 31, 2022 36,868.79
Dec 31, 2021 38,170.88
Sep 30, 2021 34,146.26